Prana discontinues PBT1 development
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Further development of Prana's investigational Alzheimer's agent clioquinol (PBT1) is "not warranted," the Australian firm says April 11. The firm has decided not to begin the "potentially pivotal" Phase II/III PLACQUE trial after finding that "unacceptably high levels of a di-iodo (toxic) form of PBT1" occur in the synthetic process of the drug. While Prana "has considered methods to reduce the levels of di-iodo impurity, it has come to the conclusion that attempts to reduce the impurity to safe levels are not likely to be successful in a timely manner." A "strategic review" of Prana's R&D programs is underway; a follow-on compound to PBT1 - PBT2 - is in Phase I...
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.